# | Title | Journal | Year | Citations |
---|
1 | Pain catastrophizing: a critical review | Expert Review of Neurotherapeutics | 2009 | 1,022 |
2 | Transition from acute to chronic postsurgical pain: risk factors and protective factors | Expert Review of Neurotherapeutics | 2009 | 607 |
3 | Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications | Expert Review of Neurotherapeutics | 2008 | 493 |
4 | Internet-based psychological treatments for depression | Expert Review of Neurotherapeutics | 2012 | 438 |
5 | The intolerance of uncertainty construct in the context of anxiety disorders: theoretical and practical perspectives | Expert Review of Neurotherapeutics | 2012 | 388 |
6 | Bupropion: pharmacology and therapeutic applications | Expert Review of Neurotherapeutics | 2006 | 312 |
7 | Role of central dopamine in pain and analgesia | Expert Review of Neurotherapeutics | 2008 | 312 |
8 | Sacroiliac joint pain: a comprehensive review of epidemiology, diagnosis and treatment | Expert Review of Neurotherapeutics | 2013 | 291 |
9 | Drug interactions involving the new second- and third-generation antiepileptic drugs | Expert Review of Neurotherapeutics | 2010 | 288 |
10 | Gait training strategies to optimize walking ability in people with stroke: a synthesis of the evidence | Expert Review of Neurotherapeutics | 2007 | 287 |
11 | Cyberchondria: towards a better understanding of excessive health-related Internet use | Expert Review of Neurotherapeutics | 2013 | 273 |
12 | Protective roles of intestinal microbiota derived short chain fatty acids in Alzheimer’s disease-type beta-amyloid neuropathological mechanisms | Expert Review of Neurotherapeutics | 2018 | 247 |
13 | The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder | Expert Review of Neurotherapeutics | 2010 | 245 |
14 | Distinguishing Alzheimer’s disease from other major forms of dementia | Expert Review of Neurotherapeutics | 2011 | 241 |
15 | Diet and Alzheimer’s disease risk factors or prevention: the current evidence | Expert Review of Neurotherapeutics | 2011 | 231 |
16 | Functional neuroimaging studies of post-traumatic stress disorder | Expert Review of Neurotherapeutics | 2011 | 231 |
17 | The interplay between gait, falls and cognition: can cognitive therapy reduce fall risk? | Expert Review of Neurotherapeutics | 2011 | 230 |
18 | Environmental factors in multiple sclerosis | Expert Review of Neurotherapeutics | 2013 | 229 |
19 | Abnormal endogenous pain modulation is a shared characteristic of many chronic pain conditions | Expert Review of Neurotherapeutics | 2012 | 228 |
20 | The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence | Expert Review of Neurotherapeutics | 2015 | 221 |
21 | Clinical implications of a staging model for bipolar disorders | Expert Review of Neurotherapeutics | 2009 | 214 |
22 | Loss of motor function in preclinical Alzheimer’s disease | Expert Review of Neurotherapeutics | 2011 | 200 |
23 | The use of ketamine in complex regional pain syndrome: possible mechanisms | Expert Review of Neurotherapeutics | 2011 | 198 |
24 | Effect of second-generation antipsychotics on cognition: current issues and future challenges | Expert Review of Neurotherapeutics | 2010 | 188 |
25 | Intracerebral hemorrhage: an update on diagnosis and treatment | Expert Review of Neurotherapeutics | 2019 | 186 |
26 | Duloxetine in the treatment of major psychiatric and neuropathic disorders | Expert Review of Neurotherapeutics | 2008 | 184 |
27 | Multiple sclerosis-associated fatigue | Expert Review of Neurotherapeutics | 2010 | 184 |
28 | Focused ultrasound-mediated drug delivery through the blood–brain barrier | Expert Review of Neurotherapeutics | 2015 | 181 |
29 | Long-acting injectable naltrexone for the treatment of alcohol dependence | Expert Review of Neurotherapeutics | 2007 | 180 |
30 | Behavioral, neurocognitive and treatment overlap between attention-deficit/hyperactivity disorder and mood instability | Expert Review of Neurotherapeutics | 2009 | 180 |
31 | Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy | Expert Review of Neurotherapeutics | 2009 | 178 |
32 | Neurologic bases for comorbidity of balance disorders, anxiety disorders and migraine: neurotherapeutic implications | Expert Review of Neurotherapeutics | 2011 | 177 |
33 | Family accommodation in obsessive–compulsive disorder | Expert Review of Neurotherapeutics | 2012 | 177 |
34 | Oxidative stress and Alzheimer’s disease: dietary polyphenols as potential therapeutic agents | Expert Review of Neurotherapeutics | 2010 | 175 |
35 | Clinical assessment and treatment of attention deficit hyperactivity disorder in adults | Expert Review of Neurotherapeutics | 2005 | 172 |
36 | Cognitive bias modification for anxiety: current evidence and future directions | Expert Review of Neurotherapeutics | 2011 | 168 |
37 | Immune therapy in autoimmune encephalitis: a systematic review | Expert Review of Neurotherapeutics | 2015 | 168 |
38 | The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson’s disease | Expert Review of Neurotherapeutics | 2016 | 168 |
39 | Speech treatment for Parkinson’s disease | Expert Review of Neurotherapeutics | 2008 | 163 |
40 | An update on the comorbidity of ADHD and ASD: a focus on clinical management | Expert Review of Neurotherapeutics | 2016 | 163 |
41 | Maladaptive plasticity, memory for pain and phantom limb pain: review and suggestions for new therapies | Expert Review of Neurotherapeutics | 2008 | 159 |
42 | Convection-enhanced delivery for the treatment of brain tumors | Expert Review of Neurotherapeutics | 2009 | 157 |
43 | Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS | Expert Review of Neurotherapeutics | 2004 | 156 |
44 | Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas | Expert Review of Neurotherapeutics | 2010 | 155 |
45 | Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders | Expert Review of Neurotherapeutics | 2010 | 152 |
46 | Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use | Expert Review of Neurotherapeutics | 2016 | 150 |
47 | Refractory epilepsy: mechanisms and solutions | Expert Review of Neurotherapeutics | 2006 | 148 |
48 | Neonatal hypoxic ischemic encephalopathy: an update on disease pathogenesis and treatment | Expert Review of Neurotherapeutics | 2017 | 148 |
49 | Current treatment options for meningioma | Expert Review of Neurotherapeutics | 2018 | 147 |
50 | Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder | Expert Review of Neurotherapeutics | 2008 | 146 |